November 12, 2012 Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
September 18, 2012 Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
August 8, 2012 Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
May 14, 2012 Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
